| Literature DB >> 28326328 |
Christine Brütting1, Alexander Emmer2, Malte E Kornhuber2, Martin S Staege3.
Abstract
At least 8% of the human genome is composed of endogenous retrovirus (ERV) sequences. ERVs play a role in placental morphogenesis and can sometimes protect the host against exogenous viruses. On the other hand, ERV reactivation has been found to be associated with different diseases, for example, multiple sclerosis (MS), schizophrenia, type 1 diabetes mellitus (T1D), or amyotrophic lateral sclerosis (ALS). Little is known about the cooccurrence of these diseases. If all these diseases are caused by ERV, antiretroviral therapy should perhaps also show some effects in the other diseases. Here, we summarize literature demonstrating that some ERV-associated diseases seem to appear together more often than expected, for example, MS and ALS, MS and T1D, MS and schizophrenia, or ALS and T1D. In contrast, some ERV-associated diseases seem to appear together less frequently than expected, for example, schizophrenia and T1D. Besides, some reports demonstrate amelioration of MS, ALS, or schizophrenia under antiretroviral therapy in human immunodeficiency virus-infected patients. If such results could be confirmed in larger studies, alternative therapy strategies for ERV-associated diseases like MS and schizophrenia might be possible.Entities:
Mesh:
Year: 2017 PMID: 28326328 PMCID: PMC5343228 DOI: 10.1155/2017/7973165
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Cooccurrence of diseases with possible involvement of ERV reactivation.
| Number of cases | Association between diseases | Comments | Ref. |
|---|---|---|---|
|
| |||
| 1 | n.a.(1) | Case report | [ |
| 2 | n.a.(1) | Case report | [ |
| 10 | n.a.(1) | Research study | [ |
| 1 | n.a.(1) | Case report | [ |
| n.a.(2) | Positive | Epidemiological investigation | [ |
| 3 | No association | Population-based register study | [ |
| 1 | n.a.(1) | Case report | [ |
| 67 | Positive | Population-based controlled study | [ |
| 63 | Positive | Population-based register study | [ |
| 39(3) | No association | Epidemiologic investigation | [ |
| 36 | Negative | Population-based register study | [ |
|
| |||
|
| |||
| 5 | Positive | Population-based register study | [ |
| 3 | n.a.(1) | Clinical register study | [ |
| 1 | No association | Clinical register study | [ |
| 28 | Positive | Cohort study | [ |
| n.a.(4) | Positive | Clinical register study | [ |
| 11 | Positive | Population-based cohort study | [ |
|
| |||
|
| |||
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Research study | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 7 | Positive | Epidemiologic investigation | [ |
| 143 | Positive | Clinical register study | [ |
| 1 | No association | Population-based case-control study | [ |
|
| |||
|
| |||
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | No association | Population-based register study | [ |
| 1 | n.a.(1) | Case report | [ |
| 10 | Negative | Comparative cohort study | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
|
| |||
|
| |||
| 0(5) | Negative | Population-based register study | [ |
| n.a.(6) | No association | Population-based register study | [ |
| 24 | No association | Population-based register study | [ |
| 24 | Negative | Population-based register study | [ |
|
| |||
|
| |||
| 2 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 2 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 2 | n.a.(1) | Case report | [ |
| 2 | n.a.(1) | Case report | [ |
| 2 | n.a.(1) | Case report | [ |
|
| |||
|
| |||
| 13 | n.a.(1) | Clinical register study | [ |
| 3 | n.a.(1) | Clinical cohort | [ |
| 8 | n.a.(1) | Cohort study | [ |
| 11 | n.a.(1) | Clinical cohort | [ |
| 10 | n.a.(1) | Clinical cohort | [ |
| 13 | n.a.(1) | Clinical cohort | [ |
| 1 | n.a.(1) | Clinical cohort | [ |
| 476 | n.a.(1) | Population-based register study | [ |
| 7 | n.a.(1) | Clinical cohort | [ |
| 11 | n.a.(1) | Clinical cohort | [ |
| 1 | n.a.(1) | Case report | [ |
| 28 | n.a.(1) | No data | [ |
| 68(7) | Positive | Population-based cohort study | [ |
|
| |||
|
| |||
| 216 | Positive | Clinical register study | [ |
| 43 | No association | Population-based case-control study | [ |
|
| |||
|
| |||
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 7 | n.a.(1) | Clinical register study | [ |
| 3 | n.a.(1) | Case report | [ |
| 10 | n.a.(1) | Population-based register study | [ |
| 1 | n.a.(1) | Case report | [ |
|
| |||
|
| |||
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Case report | [ |
| 1 | n.a.(1) | Retrospective hospital cohorts | [ |
| 1 | n.a.(1) | Case report | [ |
| 2 | n.a.(1) | Case report | [ |
(1)Not available, not tested, or not presented in the publication.
(2)The number of cases was not reported; the prevalence of psychotic disorders among more than 10,000 MS patients was reported as 1.3%.
(3)The number of cases was inferred from incidence as presented in the publication; the number was not explicitly reported.
(4)Not available; the number of patients was not reported.
(5)No schizophrenia cases were found among 1,154 diabetics below 27 years of age.
(6)Not available; the number of cases was not reported; the prevalence of psychoses among nearly 17,000 patients with T1D was reported as 0.8%.
(7)Number of HIV positive patients developing schizophrenia.